US 12,453,749 B2
Recombinant rhabdovirus encoding for CCL21
Philipp Mueller, Mittelbiberach (DE); Klaus Erb, Mittelbiberach (DE); Patrik Erlmann, Goetzens (AT); Tobias Friederike Nolden, Birgitz (AT); John Edward Park, Warthausen (DE); and Guido Wollmann, Innsbruck (AT)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE); and ViraTherapeutics GmbH, Innsbruck (AT)
Filed on Jun. 5, 2023, as Appl. No. 18/328,812.
Application 18/328,812 is a division of application No. 16/751,364, filed on Jan. 24, 2020, granted, now 11,707,495.
Claims priority of application No. 19153668 (EP), filed on Jan. 25, 2019.
Prior Publication US 2024/0000874 A1, Jan. 4, 2024
Int. Cl. A61K 35/766 (2015.01); A61K 9/00 (2006.01); A61K 31/4375 (2006.01); A61K 31/4704 (2006.01); A61K 31/4725 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/145 (2006.01); C07K 14/52 (2006.01); C12N 7/00 (2006.01)
CPC A61K 35/766 (2013.01) [A61K 9/0019 (2013.01); A61K 31/4375 (2013.01); A61K 31/4704 (2013.01); A61K 31/4725 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C12N 7/00 (2013.01); C12N 2760/20221 (2013.01)] 15 Claims
 
1. A composition comprising a recombinant vesicular stomatitis virus encoding in its genome a vesicular stomatitis virus nucleoprotein (N), large protein (L), phosphoprotein (P), matrix protein (M), glycoprotein (G) wherein, the gene coding for the glycoprotein G of the vesicular stomatitis virus is replaced by the gene coding for the glycoprotein GP of lymphocyte choriomeningitis virus (LCMV), and/or the glycoprotein G is replaced by the glycoprotein GP of LCMV, wherein the VSV does not include within its genome an additional cargo, and wherein
the nucleoprotein (N) comprises an amino acid as set forth in SEQ ID NO:7 or a functional variant at least=98% identical to SEQ ID NO:7,
the phosphoprotein (P) comprises an amino acid as set forth in SEQ ID NO:8 or a functional variant at least=98% identical to SEQ ID NO:8,
the large protein (L) comprises an amino acid as set forth in SEQ ID NO:9 or a functional variant at least=98% identical to SEQ ID NO:9,
the matrix protein (M) comprises an amino acid as set forth in SEQ ID NO:10 or a functional variant at least=98% identical to SEQ ID NO:10, and
a PD-1 pathway inhibitor, wherein the PD-1 pathway inhibitor is an antagonistic antibody which is directed against PD-1
wherein said composition of said recombinant vesicular stomatitis virus is administered concomitantly, sequentially or alternately with the antagonistic antibody against PD-1.